Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Nature Publishing Group full text link Nature Publishing Group Free PMC article
Full text links

Actions

Review
.2014 Apr;11(4):218-31.
doi: 10.1038/nrcardio.2014.1. Epub 2014 Jan 21.

Potential drug targets for calcific aortic valve disease

Affiliations
Review

Potential drug targets for calcific aortic valve disease

Joshua D Hutcheson et al. Nat Rev Cardiol.2014 Apr.

Abstract

Calcific aortic valve disease (CAVD) is a major contributor to cardiovascular morbidity and mortality and, given its association with age, the prevalence of CAVD is expected to continue to rise as global life expectancy increases. No drug strategies currently exist to prevent or treat CAVD. Given that valve replacement is the only available clinical option, patients often cope with a deteriorating quality of life until diminished valve function demands intervention. The recognition that CAVD results from active cellular mechanisms suggests that the underlying pathways might be targeted to treat the condition. However, no such therapeutic strategy has been successfully developed to date. One hope was that drugs already used to treat vascular complications might also improve CAVD outcomes, but the mechanisms of CAVD progression and the desired therapeutic outcomes are often different from those of vascular diseases. Therefore, we discuss the benchmarks that must be met by a CAVD treatment approach, and highlight advances in the understanding of CAVD mechanisms to identify potential novel therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

Competing interests

J. D. Hutcheson declares an association with the following organization: AHA. E. Aikawa declares an association with the following organization: NIH National Heart, Lung, and Blood Institute. W. D. Merryman declares associations with the following organizations: AHA and NIH National Heart, Lung, and Blood Institute. See the article online for full details of the relationships.

Figures

Figure 1
Figure 1
Cardiovascular inflammation and calcification. a | Mouse aortic valve leaflets have a similar gross morphology to human leaflets. b | Molecular imaging can be used to identify a high level of inflammation in the leaflets. c | This inflammation is closely associated with regions of calcification. d | The association between calcification and inflammation is observed throughout cardiovascular tissues. Panels a–c reprinted from Aikawa, E.et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease.Circulation119 (13), 1785–1794 (2009). Panel d reprinted from Aikawa, E.et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imagingin vivo. Circulation116 (24), 2841–2850 (2007).
Figure 2
Figure 2
Structure–function relationship in aortic valve biomechanics. a | Systolic contraction of the left ventricle forces the aortic valve leaflets to open, allowing blood to enter the aorta. b | The reversed pressure gradient, created when the heart rests in diastole, causes the aortic valve leaflets to close, preventing retrograde blood flow into the heart. The circumferential alignment of collagen allows the leaflets to stretch in the radial direction so that apposing leaflets meet and seal the valve annulus, while providing the tensile strength required to prevent leaflet prolapse. c | Imaging of picrosirius red stained collagen fibres using polarized light illustrates the alignment of collagen fibres within the aortic valve leaflets. Panel c reprinted from Aikawa, E.et al. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering.Circulation113 (10), 1344–1352 (2006).
Figure 3
Figure 3
The evolution ofin vitro calcific nodules. a | Early studies reported calcific nodules formed by apoptotic VICs in culture after treatment with transforming growth factor β1. b | Subsequent studies showed the formation of dystrophic calcific nodules in real-time owing to aggregation of myofibroblastic VICs. c | This aggregation process is exacerbated by the addition of mechanical strain, where a necrotic core (red fluorescence) is surrounded by a ring of apoptotic VICs (green fluorescence)., d | Calcific nodules with osteogenic characteristics (osteopontin staining shown) can be generated on soft culture substrates. These nodules have a similar morphology to dystrophic nodules with VICs radiating from the nodule. e | By contrast, alizarin red staining of calcification in smooth muscle cell cultures is observed in association with intact smooth muscle cells (arrow). Abbreviation: VIC, valvular interstitial cell. Panel a reprinted fromAnn. Thorac. Surg.75 (2) Jian, B.et al. Progression of aortic valve stenosis: TGF-1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. 457–765 © 2003, with permission from Elsevier. Panel b reprinted from Benton, J. A.et al. Statins block calcific nodule formation of valvular interstitial cells by inhibiting α-smooth muscle actin expression.Atheroscler. Thromb. Vasc. Biol.29 (11), 1950–1957 (2009). Panel c reprinted from Hutcheson, J. D.et al. Cadherin-11 regulates cell–cell tension necessary for calcific nodule formation by valvular myofibroblasts.Atheroscler. Thromb. Vasc. Biol.33 (1) 114–120 (2013). Panel d reprinted from Yip, C. Y.et al. Calcification by calve interstitial cells is regulated by the stiffness of the extracellular matrix.Atheroscler. Thromb. Vasc. Biol.29 (6), 936–942 (2009).
Figure 4
Figure 4
Biomechanical consequence of cardiovascular calcification. a | Aortic valve leaflets rely on appropriate biomechanical responses to open during systole and seal the valve during diastole. Similarly, vessels expand under systolic pressure. b | However, fibrocalcific remodelling is detrimental to aortic valve function. Leaflet stiffening in calcific aortic valve disease impairs the opening and closing of the leaflets. Localized calcification is not detrimental to vessel function, and fibrotic collagen accumulation is often desired to stabilize atherosclerotic plaques and prevent thrombosis.
See this image and copyright information in PMC

References

    1. Go AS, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127:e6–e245. - PMC - PubMed
    1. Nkomo VT, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005–1011. - PubMed
    1. Rajamannan NM, et al. Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124:1783–1791. - PMC - PubMed
    1. Bach DS. Prevalence and characteristics of unoperated patients with severe aortic stenosis. The Journal of heart valve disease. 2011;20:284–291. - PubMed
    1. Lindman BR, Bonow RO, Otto CM. Current management of calcific aortic stenosis. Circulation research. 2013;113:223–237. - PMC - PubMed

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full text links
Nature Publishing Group full text link Nature Publishing Group Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp